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FertilityAbstract Background: Scattered radiation to organs at risk deserves great attention during radio-
therapy especially when the concern is about fertility. Minimizing the delivery of scattered radiation
to the gonads while treating abdominal nodes or pelvic ﬁelds in male patients requires adequate
shielding of the testes to preserve testicular functions. We constructed a testicular shield with
cerrobend for the purpose of treatment of seminoma of testis stage I and IIA disease.
Materials & methods: An outer shell of coconut of required dimensions was taken as a base over
which cerrobend was poured to obtain two semi-spherical half testicular shields. Five patients of
seminoma early stage (stage I and IIA) were treated with this testicular shield.
Results: The estimated total dose received by the testis by scatter radiation after completion of the
treatment was 0.115 Gy (0.28%) of total mid-plane dose of 40 Gy delivered by inverted Y ﬁeld. At a
distance of 8 cm from the inferior ﬁeld border the 2 cm thick cerrobend testicular shield provided a
shielding factor of 3.2/0.3 = 10.33.
Conclusions: With proper testicular shielding, doses as low as 0.28% of the prescribed dose can be
achieved. This low dose is believed to maintain the fertility of the patient.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.Introduction
Scattered radiation to organs at risk deserves great attention
during radiotherapy especially when the concern is about
fertility. The main source of scattered radiation is the leakage
from collimator and internal scatter within the body of the pa-
tient [1]. In the developing countries, teletherapy with cobalt60
machine is still the primary mode of radiotherapy. The main
problem with the cobalt machine is the low beam energy which
leads to higher peripheral doses, doses as high as 20% of the
Table 1 Measured dose in phantom expressed as % of the
mid plane dose delivered to the patient.
Distance
from ﬁeld
inferior
border in
cm
Percentage
of dose
without
shielding
Percentage
of dose in
lower
half shield
alone
Percentage of dose
in lower + upper
half of shielding
together
3.5 6.5 3.8 0.9
8.0 3.2 1.3 0.3
Table 3 Energy of the scatter reaching the point proximal to
the radiation ﬁeld.
Long axis of
primary ﬁeld in cm
Scatter photon energy for
1.25 MeV (Co60) mean at 6 cm (keV)
22 789
35 673
100 M.K. Singhal et al.central axis dose is delivered at a distance of 2 cm from beam
edge of cobalt machine [2]. Maintenance of reproductive
function is one of the most asked questions to a radiation
oncologist when treating a patient of the young age group.
Minimizing the delivery of scattered radiation to the gonads
while treating abdominal nodes or pelvic ﬁelds in male patients
requires adequate shielding of the testes to preserve testicular
functions. Chao et al. reported that doses of more than
50 cGy to the gonads and cumulative dose of more than
200 cGy may lead to permanent sterility [1]. This necessitates
the adequate shielding of the testis to less than 2% of the rec-
ommended dose. Purdy et al. used a secondary gonadal shield
made up of cerrobend for use in the pelvic irradiation of males
was designed and found that the gonadal dose was reduced to
approximately 1.5–2.5% of the given dose [4]. Fraass et al. de-
scribed the use of specially made testicular shield device to
achieve less than 1.5% mean prescribed dose [5]. Bieri et al.
evaluated the inﬂuence of different shielding conditions and
ﬁeld geometry on the scatter dose to the remaining testicle dur-
ing postoperative radiotherapy in seminoma and reported sig-
niﬁcant reduction in the dose [6]. We constructed a testicular
shield with cerrobend for the purpose of treatment of semi-
noma of testis Stage I and IIA disease.
Material and method
An outer shell of a coconut of required dimensions was taken as
a base over which cerrobend was poured to obtain two semi-
spherical half testicular shields. Cerrobend was chosen as it is
light weight and has a low melting point. After drying the pre-
pared shield had an outer diameter of 8 cm and inner diameter
of 6 cm. At one of the shields, a V shaped cut was made on the
top portion for the insertion of scrotum. Inner surface was fur-
ther smoothened by the use of dental wax coating. This was done
to minimize backscatter of electrons from the shield. The
abdominal part of standard humanoid phantom (Male Alder-
son Rando phantom, Imaging solutions, Australia) was irradi-
ated simulating the patient’s treatment conditions to measure
the dose delivered by inverted Y ﬁeld. Farmer ionization cham-Table 2 Measured testis dose by TLD during treatment on differen
Patient number 1 2
Field AP PA AP PA
Measurement no. 1 0.43 0.53 0.54 0.63
Measurement no. 2 0.56 0.58 0.49 0.47
Measurement no. 3 0.48 0.46 0.63 0.64
Mean 0.49 0.52 0.55 0.58
Standard deviation 0.065 0.060 .070 0.095ber (0.6 cc) with a build up cap was used to measure the scatter
radiation inside the testicular shield.
Five patients with median age of 32 years were treated for
early stage (Stage I and IIA) seminoma testis with therateron
780E and 780C cobalt60 teletherapy machine with testicular
shield in place. 40 Gy dose was prescribed in 20 fractions
delivering 2 Gy per fraction and 5 fractions per week. The testic-
ular shield was supported by a rectangular sponge placed be-
tween the thighs. A modiﬁed dog-leg ﬁeld was used to
encompass the nodal regions at risk. The superior border was
placed at the junction of T10-T11 vertebra and the lower border
at the level superior aspect of the acetabulum.
Polythene bagwas used to place the uninvolved testis inside the
shield. The dose delivered to testis despite shielding measured with
the help of precalibrated CaSo4:Dy thermo luminescent disc
(TLD) of size 9 mm · 13 mm was placed on scrotal surface. The
scattered dose received by TLD was measured by NUCLEONIX
TL 10091 TLD reader. After one set of measurement, the discs
were annealed by heating up to 400 Cand then used for nextmea-
surements carried out at 1st week, 2nd week, and 3rd week. The
readings of the TLD were compared with those obtained from
the detectors exposed to aknownandﬁxeddose in the tissue equiv-
alent phantom at the depth of 5 cm to calculate the absorbed dose
in cGy.
The energy of scattered photon was calculated utilizing the
standard formula for Compton scattering (Eq. (1)). The energy
of the incident beam (hv) was taken as 1.25 MeV.
E ¼ hv 1 1þ hv
m0c2
 
ð1 cosaÞ
   
ð1ÞResults
Table 1 depicts the doses asmeasured by the ionization chamber
in the phantom in the absence of testicular shield; the doses were
6.5% and 3.2%of themid-plane dose at the central axis at a dis-
tance of 3.5 and 8 cm from the proximal edge of the ﬁeld respec-
tively. When the shield was used in lower half, these doses
reduced to 3.8% and 1.3%, respectively, while when both upper
and lower half shieldswere placed in position, the corresponding
doses were 1.2% and 0.6%. ThemeanAP doses in the 5 patients
were 0.563 CGy (±0.123) while the mean PA dose wast days.
3 4 5
AP PA AP PA AP PA
0.87 0.90 0.65 0.56 0.67 0.76
0.57 0.49 0.37 0.57 0.56 0.49
0.67 0.54 0.47 0.58 0.48 0.58
0.70 0.64 0.49 0.57 0.57 0.61
0.152 0.223 0.141 .010 0.095 0.137
Table 4 Scattered radiation doses at the testis from different previous studies.
No. Report
taken from
Energy of
photon beam
Percentage of testicular
dose without shielding
AP ﬁeld with
shield
Percentage of testicular
dose without shielding
PA ﬁeld with
shield
1 Bieri et al. 18 MV 1.95% 0.74% 0.93% 0.33%
2 Fraass et al. 10 MV 2.00% 0.40% 2.5% 0.5%
3 Purdy et al. – 4–6% 1.5–2.5% – –
Scattered radiation to gonads 1010.585 CGy (±0.116). Table 2 shows the measured testicular
dose by TLD during treatment in three different days. The
estimated total dose received by the testis by scatter radiation
after completion of the treatment was 0.115 Gy (0.28%) of total
mid-plane dose of 40 Gy delivered by inverted Y ﬁeld. The en-
ergy of scattered photon at 6 cm measured by the standard for-
mula ofCompton scattering for 1.25 MeV energy beam is shown
in Table 3. For a ﬁeld of 22 cm, a 1.25 MeV photon beam gave a
scattered energy of 789 kev at 6 cm from the gonads (Table 4).
Discussion
Fertility sparing radiotherapy is a challenge to the radiation oncolo-
gist while treating the pelvic ﬁelds in young male patients. As testes
are highly radiosensitive, doses as low as 200 cGy can cause perma-
nent infertility causing signiﬁcant impairment in the quality of life
of these patients due topsychosocial dysfunction.Weused2 cm thick
testicular shield made of cerrobend to effectively shield the gonads to
receive only 0.28%of the prescribeddose of 40 Gy.This iswell below
the required limit of 2% of the prescribed dose. Ravichandran et al.
usedasimilar shieldof1.5 cmthickness to treat apatientof seminoma
with15MeVX-raybeamsand found that a scattereddoseof 0.8%of
prescribed dose of 40 Gy was to be delivered to the uninvolved
shielded testis [7]. At a distance of 8 cm from the inferior ﬁeld border
the 2 cm thick cerrobend testicular shield provided a shielding factor
of 3.2/0.3 = 10.33. The upper limit of the testicular shield is believed
to reduce thescatter radiationarising fromthecollimatorof thecobalt
machinewhile the lowerhalf shields the internal scatteringdosearising
from the irradiated volume in the abdomen.
Inour studyas derivedbyphantomdosimetry,we found that per-
centage of dose delivered with only lower half shield in position was
1.3% as against 3.2% in unshielded condition when both upper
and lower shields were placed only 0.6%dose was delivered.Murthy
et al. studied the effect ofﬁeld size, penumbra trimmers andback scat-
termedium [3]. Purdy et al. reported that shielding only at the level of
collimator is not sufﬁcient to decrease the radiation dose to the go-
nads. Thus, additional shielding directly around the testis is recom-
mended [4]. The gonad shield used in our study is different from
that used in the previous literature. First, the shape of the shield used
is spherical as against box-shaped in earlier reports. The spherical
shape of the shield not only shields the testis from scattered photons
coming from all the direction, but it is also much lighter. Besides
the spherical shape, the composition of the shield in our care is cerro-
bend, a lowmeltingpoint and lighter alloymaking it suitable for daily
clinical use. Fraass et al. reported the relation between the measured
dose and depth of measurement within the shield to be insigniﬁcant.
Also, they reported that only low energy photons are exposed at the
level of the gonads [5]. In their study, for patients treated with para-
aortic and homolateral iliac ﬁelds, the mean testicular doses per frac-
tion were 3.89 cGy (S.D.± 1.44) and 1.48 cGy (S.D.± 0.51) with-
out and with gonadal shielding, respectively (P-value <0.001); thecorresponding values for exclusive para-aortic ﬁelds were 1.86 cGy
(S.D. ± 0.86) and 0.65 cGy (S.D. ± 0.35). [5] Similarly, we found
that in patients treated with para-aortic and homolateral iliac nodal
radiotherapy, the mean testicular dose after shielding was only
0.572 cGy. Thus, a testicular shield of 2 cm thickness is clearly ade-
quate for the required purpose.
Conclusions
With proper testicular shielding, doses as low as 0.28% of the
prescribed dose can be achieved. This low dose is believed to
maintain the fertility of the patient.
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